A combination of anti the programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies is currently being evaluated in clinical trials for liver cancer. The gene discussed is CTLA4; the disease is liver cancer.